Suppr超能文献

一些新型、高活性的16α,17α-缩醛取代糖皮质激素的化学结构、受体结合与生物活性之间的相关性

Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids.

作者信息

Dahlberg E, Thalén A, Brattsand R, Gustafsson J A, Johansson U, Roempke K, Saartok T

出版信息

Mol Pharmacol. 1984 Jan;25(1):70-8.

PMID:6708937
Abstract

The affinity for the glucocorticoid receptor in rat skeletal muscle of some glucocorticoids with a new type of 16 alpha, 17 alpha-acetal substituent has been estimated and correlated to the glucocorticoid activities in three in vivo systems in rats. Budesonide (an approximately 1:1 mixture of the C(22) epimers of 11 beta, 21-dihydroxy-16 alpha, 17 alpha-[(22R,S)-propylmethylenedioxy]-pregna-1,4-diene-3,20-dione) and the isolated (22R)- and (22S)-epimers bound to the same binding site as the potent glucocorticoids dexamethasone (DEX) or triamcinolone 16 alpha, 17 alpha-acetonide (TA), but with even higher affinity than DEX or TA, despite the lack of a 9 alpha-fluoro atom in budesonide and its epimers. The (22R)-epimer was twice as active as the (22S)-epimer, 4 times more active than TA, and 14 times more active than DEX. The introduction of a 9 alpha-fluoro atom slightly decreased the binding affinity of the (22R)-epimer of budesonide, in contrast to the positive effect of 9 alpha-fluorination of, e.g., 16 alpha, 17 alpha-acetonides. The negative influence of 9 alpha-fluorination of the (22R)-epimer was partially reversed in the 6 alpha, 9 alpha-difluorinated (22R)-epimer. Nevertheless, the fluorinated compounds were more active than DEX and TA (8 and 11 times more active than DEX, and 2 and 3 times more active than TA, in case of the 9 alpha-fluoro- and 6 alpha, 9 alpha-difluoro-derivatives of the (22R)-epimer, respectively). Budesonide is metabolized mainly to 16 alpha-hydroxyprednisolone (11 beta, 16 alpha, 17 alpha, 21-tetrahydroxy-pregna-1,4-diene-3,20-dione) and 6 beta-hydroxy-budesonide. Both metabolites were very weak competitors for the ligand-binding sites on the receptor (3% and 6% of the affinity of DEX, respectively). The affinity for the receptor in vitro was closely correlated to the topical glucocorticoid activity in vivo for the 12 steroids compared (r = 0.98; R = 0.98), which supports the contention that in vitro tests for receptor affinity are useful when screening for agonists among steroids with the present type of structures. The results on receptor-ligand interaction are in accordance with X-ray crystallographic data available for some steroids.

摘要

已对一些带有新型16α,17α-缩醛取代基的糖皮质激素与大鼠骨骼肌中糖皮质激素受体的亲和力进行了评估,并将其与大鼠体内三个系统中的糖皮质激素活性相关联。布地奈德(11β,21-二羟基-16α,17α-[(22R,S)-亚丙基二氧基]-孕甾-1,4-二烯-3,20-二酮的C(22)差向异构体的约1:1混合物)以及分离出的(22R)-和(22S)-差向异构体与强效糖皮质激素地塞米松(DEX)或曲安奈德16α,17α-丙酮化物(TA)结合于相同的结合位点,但尽管布地奈德及其差向异构体中没有9α-氟原子,它们的亲和力却比DEX或TA更高。(22R)-差向异构体的活性是(22S)-差向异构体的两倍,比TA高4倍,比DEX高14倍。与例如16α,17α-丙酮化物的9α-氟化的积极作用相反,9α-氟原子的引入略微降低了布地奈德(22R)-差向异构体的结合亲和力。(22R)-差向异构体的9α-氟化的负面影响在6α,9α-二氟化的(22R)-差向异构体中部分得到逆转。然而,氟化化合物比DEX和TA更具活性(对于(22R)-差向异构体的9α-氟代和6α,9α-二氟代衍生物,分别比DEX高8倍和11倍,比TA高2倍和3倍)。布地奈德主要代谢为16α-羟基泼尼松龙(11β,16α,17α,21-四羟基-孕甾-1,4-二烯-3,20-二酮)和6β-羟基布地奈德。两种代谢产物都是受体上配体结合位点的非常弱的竞争者(分别为DEX亲和力的3%和6%)。在所比较的12种甾体中,体外对受体的亲和力与体内局部糖皮质激素活性密切相关(r = 0.98;R = 0.98),这支持了以下观点:在筛选具有当前结构类型的甾体激动剂时,体外受体亲和力测试是有用的。受体 - 配体相互作用的结果与一些甾体的X射线晶体学数据一致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验